ARGO

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
星期二, 五月 7, 2024
Komodo, Psoriatic arthritis, VELA, FDA, American Academy, Porokeratosis, Psoriasis, HS, Skin, Rheumatology, MDA, Research, Partnership, Conference, PPP, MIRA, Joint, Bimekizumab, Patient, EMA, AAD, Inflammation, PASI, Moonlake, Dermatology, ARGO, Pharmaceutical industry

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.
  • Research and development expenses for the quarter ended March 31, 2024, were $13.0 million, compared to $8.1 million in the previous quarter.
  • The increase was primarily due to expenses incurred to initiate the new clinical trials.
  • General and administrative expenses for the quarter ended March 31, 2024 were $6.8 million, similar to the $6.9 million incurred in the previous quarter.

DigiLens Licensee Crystal-Optech Makes Significant Upgrades to Their State-of-the-Art Manufacturing Line to Support a Wave of Global Demand

Retrieved on: 
星期三, 五月 1, 2024
Mobile, Wireless, Hardware, Electronic Design Automation, Consumer Electronics, Technology, Semiconductor, Other Manufacturing, Nanotechnology, Engineering, Wearables, Mobile Technology, Manufacturing, Telecommunications, Lens, XR, Partnership, Crystal, ARGO, Ceramic

This will allow DigiLens to support the growing demand from the consumer and enterprise sectors, and increase production of ​​​​ARGO, the first purpose-built, standalone AR/XR device designed for enterprise and lite-industrial markets.

Key Points: 
  • This will allow DigiLens to support the growing demand from the consumer and enterprise sectors, and increase production of ​​​​ARGO, the first purpose-built, standalone AR/XR device designed for enterprise and lite-industrial markets.
  • With this upgrade, DigiLens’ latest waveguide technologies will be positioned to support the development of future projects and higher demand at scale.
  • Crystal-Optech is a leading optical elements manufacturer of optical coating, AR optics, and semiconductor optics.
  • The lenses manufactured by Crystal-Optech will enable DigiLens to address the increasing demand in the space and for its ARGO mobile computing glasses.”

DigiLens ARGO™ Now Certified for Use with Leading Mobile Device Management (MDM) Solution Microsoft Intune

Retrieved on: 
星期二, 三月 19, 2024
Technology, Other Technology, Audio, Video, Mobile, Wireless, Software, Wearables, Mobile Technology, Hardware, Diamond, ARGO, Microsoft, OS, Continental AG, Qualcomm Snapdragon, Organization, Augmented reality, Microsoft Intune, XR, AOSP, Universal Display Corporation, MDM, Samsung Electronics, Samsung Electro-Mechanics, GameWeek Magazine, OEM, Mitsubishi Chemical Holdings, API, Niantic, Inc., Multimedia, Android, Human, Video game

DigiLens Inc., a leading nanotechnology innovator in waveguide display technologies and XR smartglasses, announces that its flagship Augmented Reality (AR) device, the DigiLens ARGO™, has been certified for use with Microsoft Intune , a leading cloud-based MDM solution.

Key Points: 
  • DigiLens Inc., a leading nanotechnology innovator in waveguide display technologies and XR smartglasses, announces that its flagship Augmented Reality (AR) device, the DigiLens ARGO™, has been certified for use with Microsoft Intune , a leading cloud-based MDM solution.
  • View the full release here: https://www.businesswire.com/news/home/20240319733368/en/
    DigiOS, ARGO's spatial-based OS, now certified for use with Microsoft Intune.
  • Microsoft Intune (part of Microsoft Endpoint Manager) offers support for AOSP (Android Open Source Program) device management.
  • Intune joins ArborXR as part of DigiLens’ expanding list of MDM solutions that enable enterprise customers to provision, configure, and secure DigiLens devices.

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Retrieved on: 
星期日, 三月 10, 2024
Psoriatic arthritis, ACR, Doctor of Philosophy, Adalimumab, Skin, American College, Webcast, Moonlake, HS, Patient, Psoriasis, VELA, MMSc, ARGO, MIRA, EDT, Physician, Inflammation, Safety, Prognosis, Clinical trial, Ankylosing spondylitis, TNF, IL-17A, MDA, American Academy, EMA, Medical college, FDA, Food, Steroid, Prevalence, AAD, Event, Joint, PASI, Hidradenitis suppurativa, PSA, PPP, Disease, Porokeratosis, Medicine, Pharmaceutical industry

In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.

Key Points: 
  • In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.
  • Treatment with sonelokimab resulted in unprecedented improvements in composite scores that reflect responses in different domains simultaneously.
  • In all composite scores, sonelokimab showed 16-29 percentage point differences to the reference adalimumab arm, comparatively higher to competitors using the same reference arm.
  • The discontinuation rate of the second part of ARGO remained low at 5%, in line with other sonelokimab trials.

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

Retrieved on: 
星期四, 二月 29, 2024
MIRA, Psoriatic arthritis, EMA, Research, VELA, Medical college, Inflammation, FDA, Investment, Assessment, Conference, AAD, Rheumatology, Event, ARGO, Hidradenitis suppurativa, Webcast, Patient, Science, American Academy, Pharmaceutical industry

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2023 was another momentous year for MoonLake in the inflammation and immunology field.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2023 was another momentous year for MoonLake in the inflammation and immunology field.
  • On top of this, support from world-renowned experts, clinicians, and patient organizations for our data, science and methodologies continues to mount.
  • Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics, said: “MoonLake has added considerable shareholder value over the past year, and we are driven to continue building on this.
  • Other non-operating income increased from $0.6 million in the prior year to $10.1 million for the year ended December 31, 2023.

DigiLens Expands Technology Ecosystem with Leading Electronics System and Design (ESDM) Manufacturer Kaynes Technology India Limited as it Prepares for Global Scale

Retrieved on: 
星期二, 一月 30, 2024
Mobile, Wireless, Other Defense, Hardware, Electronic Design Automation, Technology, Defense, Other Manufacturing, Government Technology, Engineering, Wearables, Mobile Technology, Other Technology, Manufacturing, Partnership, Growth, Apple, ARGO, Augment, Space research, Augmented reality, Meta, Original equipment manufacturer, Health, Video game

DigiLens Inc., a leading nanotechnology innovator in waveguide display technologies and headworn smartglasses, announces a collaborative partnership with India-based Kaynes Technology India Limited to scale waveguide manufacturing.

Key Points: 
  • DigiLens Inc., a leading nanotechnology innovator in waveguide display technologies and headworn smartglasses, announces a collaborative partnership with India-based Kaynes Technology India Limited to scale waveguide manufacturing.
  • Kaynes Technology and DigiLens will collaborate through Kaynes Semicon Pvt Ltd, a 100% subsidiary of Kaynes Technology, at their Green Field facility in Hyderabad.
  • DigiLens’ optical platform allows OEMs to create customizable, cost-effective waveguide-based AR experiences for both enterprise and consumer applications.
  • “We are excited to be working with Kaynes Technology because of their advanced manufacturing and design presence in India.

Alliance of Responsible Gun Ownership (ARGO) Launches Nonprofit Division

Retrieved on: 
星期一, 一月 22, 2024
Organization, Safety, Freedom, ARGO

This new division is an extension of ARGO's commitment to freedom, safety, transparency, trustworthiness and a moderate conversation, free from extremist narratives.

Key Points: 
  • This new division is an extension of ARGO's commitment to freedom, safety, transparency, trustworthiness and a moderate conversation, free from extremist narratives.
  • The launch of the ARGO Foundation 501©(3) marks a significant milestone in ARGO's journey, furthering its mission to promote responsible gun ownership.
  • In addition to the launch of the nonprofit division, ARGO is also expanding its alliances by adding brands and organizations that align with its mission.
  • "We are excited about the launch of our nonprofit division and the expansion of our alliances," said Michael Pierce, the Founder & CEO of ARGO.

Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids

Retrieved on: 
星期四, 一月 4, 2024
Cytokine, Protein, Proteomics, Immune system, ARGO, Research, Workflow, Plasma, Disease, Systemic inflammation, Cancer, Stanford University, Biomarker, Inflammation, Cardiovascular disease, Nature Communications, Vaccine

FREMONT, Calif., Jan. 4, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the ARGO HT System for push-button, high sensitivity analysis of proteins in biofluids and the NULISAseq Inflammation Panel 250 for deep profiling of immune response. The ARGO HT System provides an automated method for running NULISA™ assays with less than 30 minutes of total hands-on time, reducing the variability seen with manual assay technologies while freeing up researchers' precious time. The launch of these two products represents an important milestone in the company's goal to deliver high sensitivity, high plex protein analysis to support the discovery and translation of critical biomarkers involved in disease progression and therapeutic response.

Key Points: 
  • "Last year we completed over 80 technology access projects and researchers' response to the data has been overwhelmingly positive.
  • Chronic inflammation is implicated in the development of many diseases including autoimmune disorders, neurodegenerative diseases, cardiovascular disease, and cancer.
  • "We are extremely excited to have the ARGO HT System installed and running research projects in our lab.
  • "I was especially impressed with the simplicity of the system and how quickly my team was able to become proficient.

Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids

Retrieved on: 
星期四, 一月 4, 2024
Cytokine, Protein, Proteomics, Immune system, ARGO, Research, Workflow, Plasma, Disease, Systemic inflammation, Cancer, Stanford University, Biomarker, Inflammation, Cardiovascular disease, Nature Communications, Vaccine

FREMONT, Calif., Jan. 4, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the ARGO HT System for push-button, high sensitivity analysis of proteins in biofluids and the NULISAseq Inflammation Panel 250 for deep profiling of immune response. The ARGO HT System provides an automated method for running NULISA™ assays with less than 30 minutes of total hands-on time, reducing the variability seen with manual assay technologies while freeing up researchers' precious time. The launch of these two products represents an important milestone in the company's goal to deliver high sensitivity, high plex protein analysis to support the discovery and translation of critical biomarkers involved in disease progression and therapeutic response.

Key Points: 
  • "Last year we completed over 80 technology access projects and researchers' response to the data has been overwhelmingly positive.
  • Chronic inflammation is implicated in the development of many diseases including autoimmune disorders, neurodegenerative diseases, cardiovascular disease, and cancer.
  • "We are extremely excited to have the ARGO HT System installed and running research projects in our lab.
  • "I was especially impressed with the simplicity of the system and how quickly my team was able to become proficient.

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
星期二, 十一月 14, 2023
IL-17A, Moonlake, Safety, MIRA, Psoriatic arthritis, Patient, Inflammation, Research, Calendar, HS, Conference, Antibody, Hidradenitis suppurativa, Skin, PASI, ARGO, Pharmaceutical industry, Security (finance), Vaccine

During the quarter and post period, MoonLake announced significant new positive clinical data from two global Phase 2 trials of sonelokimab: “MIRA”, in moderate-to-severe hidradenitis suppurativa (HS) and “ARGO”, in active psoriatic arthritis (PsA).

Key Points: 
  • During the quarter and post period, MoonLake announced significant new positive clinical data from two global Phase 2 trials of sonelokimab: “MIRA”, in moderate-to-severe hidradenitis suppurativa (HS) and “ARGO”, in active psoriatic arthritis (PsA).
  • The Nanobody’s® smaller size versus traditional antibodies and its albumin-binding domain provide an opportunity for further efficacy.
  • Research and development expenses for the quarter ended September 30, 2023, were $7.6 million, compared to $8.7 million in the previous quarter.
  • General and administrative expenses for the quarter ended September 30, 2023, were $5.4 million, compared to $4.5 million in the previous quarter.